Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Current Status and Perspective of Immunotherapy for Head and Neck...
share announcement

Current Status and Perspective of Immunotherapy for Head and Neck Squamous Cell Carcinoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 1688

Special Issue Editors

Dr. Amaury Daste

E-Mail Website
Guest Editor
Centre Hospitalier Universitaire de Bordeaux, 33075 Bordeaux, France
Interests: head and neck cancer; immunotherapy; targeted therapy
Prof. Dr. Wollenberg Barbara

E-Mail Website
Guest Editor
Department of Otolaryngology Head and Neck Surgery, Technical University Munich, 80333 Munich, Germany
Interests: head and neck cancer (HNSCC); tumorimmunology; immunotherapy; clinical study HNSCC; platelets; platelet-driven cancer progression; toll like receptors and cancer

Special Issue Information

Dear Colleagues,

Head and neck squamous cell carcinoma (HNSCC) is the most frequent cancer of the head and neck.

Immune-checkpoint inhibitors have changed the outcome for some for some patients with recurrent or metastatic HNSCC (R/M HNSCC).

However, most patients with HNSCC present primary or secondary resistance under anti PD1/PD-1. A number of clinical trials have failed to demonstrate efficacy in both locally advanced diseases and in RM HNSCC.

Novel biomarkers and novel strategies for association are needed to increase the efficacy of immunotherapy for head and neck cancer patients, as locally advanced diseases or in the R/M setting.

Therefore, we are looking for manuscripts covering the current status in local diseases or R/M, as well as novel strategies for use immune-checkpoint inhibitors for HNSCC. This Special Issue welcomes the submission of reviews as well as original research articles.

Dr. Amaury Daste
Prof. Dr. Wollenberg Barbara
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • head and neck cancer
  • immunotherapy
  • molecular pathogenesis
  • tumor biology
  • head and neck squamous cell carcinoma

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

22 pages, 4740 KiB  
Article
Standardized Digital Image Analysis of PD-L1 Expression in Head and Neck Squamous Cell Carcinoma Reveals Intra- and Inter-Sample Heterogeneity with Therapeutic Implications
by Eric Deuss, Cornelius Kürten, Lara Fehr, Laura Kahl, Stefanie Zimmer, Julian Künzel, Roland H. Stauber, Stephan Lang, Timon Hussain and Sven Brandau
Cancers 2024, 16(11), 2103; https://doi.org/10.3390/cancers16112103 - 31 May 2024
Abstract
For practical reasons, in many studies PD-L1 expression is measured by combined positive score (CPS) from a single tumor sample. This does not reflect the heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma (HNSCC). We investigated the extent and relevance [...] Read more.
For practical reasons, in many studies PD-L1 expression is measured by combined positive score (CPS) from a single tumor sample. This does not reflect the heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma (HNSCC). We investigated the extent and relevance of PD-L1 expression heterogeneity in HNSCC analyzing primary tumors and recurrences (LRs), as well as metastases. Tumor tissue from 200 HNSCC patients was immunohistochemically stained for PD-L1 and analyzed using image-analysis software QuPath v3.4 with multiple specimens per patient. CPS was ≥20 in 25.6% of primary tumors. Intra-tumoral heterogeneity led to a therapeutically relevant underestimation of PD-L1 expression in 28.7% of patients, when only one specimen per patient was analyzed. Inter-tumoral differences in PD-L1 expression between primary tumors and lymph node metastasis (LNM) or LR occurred in 44.4% and 61.5% (CPS) and in 40.6% and 50% of cases (TPS). Overall survival was increased in patients with CPS ≥ 1 vs. CPS < 1 in primary tumors and LNM (hazard ratio: 0.46 and 0.35; p < 0.005); CPS in LR was not prognostic. Our analysis shows clinically relevant intra- and inter-sample heterogeneity of PD-L1 expression in HNSCC. To account for heterogeneity and improve patient selection for immunotherapy, multiple sample analyses should be performed, particularly in patients with CPS/TPS < 1. Full article
(This article belongs to the Special Issue Current Status and Perspective of Immunotherapy for Head and Neck Squamous Cell Carcinoma)
►▼ Show Figures

Figure 1

Review

Jump to: Research

20 pages, 639 KiB  
Review
Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers
by Andrew Meci, Neerav Goyal and Guy Slonimsky
Cancers 2024, 16(4), 703; https://doi.org/10.3390/cancers16040703 - 7 Feb 2024
Viewed by 1314
Abstract
Immunotherapy is emerging as an effective treatment for advanced head and neck cancers and interest in this treatment modality has led to rapid expansion of this research. Pembrolizumab and nivolumab, monoclonal antibodies directed against the programmed cell death-1 (PD-1) receptor, are US Food [...] Read more.
Immunotherapy is emerging as an effective treatment for advanced head and neck cancers and interest in this treatment modality has led to rapid expansion of this research. Pembrolizumab and nivolumab, monoclonal antibodies directed against the programmed cell death-1 (PD-1) receptor, are US Food and Drug Administration (FDA)- and European Medical Agency (EMA)-approved immunotherapies for head and neck squamous cell carcinoma (HNSCC). Resistance to immunotherapy is common, with about 60% of patients with recurrent or metastatic HNSCC not responding to immunotherapy and only 20–30% of patients without disease progression in the long term. Overcoming resistance to immunotherapy is therefore essential for augmenting the effectiveness of immunotherapy in HNSCC. This review details the innate and adaptive mechanisms by which head and neck cancers can become resistant to immunotherapeutic agents, biomarkers that can be used for immunotherapy patient selection, as well as other factors of the tumor microenvironment correlated with therapeutic response and prognosis. Numerous combinations and novel immunotherapies are currently being trialed, based on better understood immune evasion mechanisms. These potential treatments hold the promise of overcoming resistance to immunotherapy in head and neck cancers. Full article
(This article belongs to the Special Issue Current Status and Perspective of Immunotherapy for Head and Neck Squamous Cell Carcinoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop